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The pathobiology of chronic allograft nephropathy: Immune-
mediated damage and accelerated aging. Chronic allograft
nephropathy includes chronic calcineurin nephrotoxicity, recur-
rent and de novo glomerulonephritis and a group of disorders
with graft dysfunction of unknown etiology designated chronic
rejection. Review of risk factors of the latter category show
that the chronic rejection lesions emerge in organs that have
undergone injury. Despite the relevance of nonalloantigen-
dependent progression factors in the tissue injury, alloantigen-
dependent factors predominate in the pathogenesis. Lately, B
cell responses have received increasing interest in transplant re-
jection and include responses against both major histocompat-
ibility complex (MHC) and tissue-specific antigens, mainly on
the endothelium and in the glomeruli. These humoral responses
are thought to be involved in the development of vascular and
glomerular lesions. Furthermore, at the tissue level, markers of
senescence are found in the tubular epithelium contributing to
the lesions of tubular atrophy and interstitial fibrosis.
Despite improvements in outcome in the early post
transplant period, improving the long-term survival of
kidney transplants remains a challenge as up to 50% of
grafts are lost from chronic allograft nephropathy. The
time to failure of a graft is determined by the initial func-
tion achieved, the number and severity of insults, and
a number of tissue characteristics. The insults a graft
usually encounters include ischemia/reperfusion injury,
rejection episodes, hypertension, smoking, drug nephro-
toxicity, and hyperlipidemia [1, 2]. The tissue susceptibil-
ity to injury and the ability to repair damage are important
tissue characteristics.
Chronic allograft nephropathy is a descriptive term
for histologic lesions in a renal allograft and includes
atherosclerosis, glomerulosclerosis, interstitial fibrosis,
and tubular atrophy [1]. Clinically, chronic allograft
nephropathy can lead to chronic transplant dysfunction,
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characterized by a decline in function and the develop-
ment of proteinuria [3]. The lesions of chronic allograft
nephropathy can originate from various causes and the
differential diagnosis includes chiefly recurrent and de
novo glomerulonephritis, chronic calcineurin inhibitor
nephrotoxicity, and a group of lesions of unknown ori-
gin called chronic rejection [3]. The diagnosis of chronic
rejection is verified by histology: the presence of glomeru-
lar and/or vascular lesions against a background of inter-
stitial fibrosis and tubular atrophy. Before establishing
the diagnosis other known causes have to be ruled out.
Immunofluorescence and electron microscopy are useful
tools in addition to histology to establish the diagnosis.
Multivariate analysis to identify risk factors for chronic
rejection revealed an important role for acute rejection
episodes after the first 3 months. Peak panel reactive an-
tibodies (PRA), PRA at the time of implantation, and
donor age have also been identified as important risk
factors [3–5]. Major histocompatibility complex (MHC)
class I histoincompatability is associated with the occur-
rence of late acute rejection episodes. Indirect presen-
tation, which is the likely antigen presentation route in
these conditions, can result in activation of CD4+ Th2
T cells, leading to B-cell activation and production of
alloantibodies [6].
Previous experiments using severe combined immun-
odeficiency (SCID) (lack B- and T-cell responses) or
immunoglobulin heavy chain (IGH) knockout (lack func-
tional B cells) mice as recipients, have shown that chronic
rejection was only induced upon transfer of alloantibod-
ies [7, 8] reactive with donor MHC antigens or with non-
MHC antigens.
Antibodies reactive with MHC antigens might be most
harmful to the endothelium. The endothelium is the first
site of contact between antibodies and the foreign MHC
antigens. Transplant vasculopathy might be the result of
anti-MHC antibodies binding in the large vessels leading
to damage.
Antibodies reactive with non-MHC antigens may re-
sult in damage to different cell types in the graft, in-
cluding endothelial cells and organ-specific cells. In
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addition, antibodies can be reactive with the renal base-
ment membranes.
HUMORAL IMMUNE RESPONSE IN
CHRONIC REJECTION
In the Fisher (F344) to Lewis (LEW) rat model of
chronic rejection we identified an antibody response reac-
tive with antigens in the glomerular basement membrane
(GBM) [9]. Antibodies were only detected posttreatment
in LEW recipients of chronically rejecting F344 grafts
but not in the long-term surviving, chronic rejection-free
F344 recipients of LEW grafts or in syngeneic transplan-
tations. The antigens were identified using proteomics
techniques, and included the basement membrane hep-
aran sulfate proteoglycan perlecan and the a1 chain of
collagen type VI in association with the a5 chain of col-
lagen type IV [9].
In patients, transplant glomerulopathy, characterized
by duplications of the GBM, is found in about 2% of
kidney transplant recipients and in about 15% of pa-
tients with chronic rejection [10] [Sijpkens et al, in press].
Risk factor analysis revealed pretransplant sensitization
and late acute rejection episodes, which are immuno-
logic risk factors. Using a polyvalent antiserum raised
against C4d peptides, C4d deposits in the glomeruli were
demonstrated, indicating that humoral responses might
be involved [Sijpkens et al, in press]. Recently, we found
antibodies reactive with GBM isolates in patients with
transplant glomerulopathy, supporting a role for hu-
moral immunity in transplant glomerulopathy [Joosten
et al, unpublished data].
In addition, responses against human leukocyte anti-
gen (HLA) and non-HLA antigens on endothelial cells
can be involved in the vascular lesions. Renal transplant
recipients with anti-HLA antibodies were five to six times
more likely to develop chronic rejection compared to pa-
tients without anti-HLA antibodies, patients who have
antibodies against both class I and II HLA antigens pre-
treatment have the worst prognosis [11, 12].
OLD DONOR AGE
An important factor in the decline of function after
acute rejection is the quality to start with, determined
by donor age and previous damage to the kidney [4].
Kidneys from older donors result in more acute rejec-
tion episodes, mainly due to an increase in the number
of interstitial rejection episodes. Furthermore, if an acute
rejection episode occurs in an older donor kidney, it re-
sults more often in graft loss compared to acute rejection
episodes in young kidneys [13]. The lesions observed in
aging kidneys are very similar to the lesions observed in
chronic allograft nephropathy. Therefore, the “aging hy-
pothesis of chronic allograft nephropathy” was proposed
[14, 15], stating that chronic allograft nephropathy might
be the result of accelerated aging of the graft.
In normal somatic cell replication, cells lose a small
part of their telomeres with each division, at least in
vitro; the cells ultimately achieve the Hayflick and Moor-
head limit [16]. The Hayflick and Moorhead limit is the
point at which the cells do not divide anymore, and at
which the cells can enter the replicative senescence state.
Telomeres protect the ends of chromosomes from degra-
dation and the telomeric repeats (TTAGGG) are ex-
tremely sensitive to oxidative damage [17]. Alterations
in telomeric structures can activate several cellular path-
ways leading to an arrest of the cell cycle. Replicative
senescence is an arrest of the cell cycle in the G1 phase,
in which the cells maintain their normal metabolic func-
tions but become desensitized to various external stimuli
and thereby contribute to persistent inflammation and
fibrosis [18]. Ischemia and reperfusion during transplan-
tation result in the production of free oxygen radicals that
can alter the telomeric structure leading to induction of
senescence.
Recently, we demonstrated telomere shortening and
the induction of replicative senescence in the F344 to
LEW rat model of chronic rejection [19]. Ischemia and
reperfusion of the kidney already induced telomere
shortening, subsequently the cell cycle regulator p21 was
transiently induced and the cell cycle regulator p16 accu-
mulated in the tubular epithelium. All these features were
found in both the rats that did develop chronic rejection
(F344 to LEW) as well as in the rats that did not develop
chronic rejection (LEW to F344), and appeared to be
the effect of the transplantation procedure rather than
a result of chronic rejection. Senescence-associated b-
galactosidase (b-Gal) is a marker of senescent cells, which
increases due to the accumulation of lysosomes, that keep
proliferating even if the cell is arrested [20]. Senescence-
associated b-Gal staining [21] was only found in tubular
epithelial cells in the F344 to LEW combination, but not
in the LEW to F344 transplants and therefore paralleled
with the lesions of chronic rejection. Thus, telomere short-
ening was not sufficient to induce senescence. In addition,
in kidneys of rats with increasing age, no telomere short-
ening was observed. However, senescence-associated b-
Gal staining was present in kidneys obtained from rats of
24 months of age [22]. Together these studies revealed
that shortening of telomeres is not sufficient and also
not required for the induction of replicative senescence.
Furthermore, the senescence-associated b-Gal staining
as found in aging rat kidneys (9 to 24 months of age) can
also be found in kidneys with chronic rejection (maxi-
mum 6 to 7 months of age) but at a much younger age,
supporting the accelerated ageing hypothesis of chronic
allograft nephropathy. The tubular epithelial cells are
most sensitive for the induction of senescence, contribut-
ing to the development of tubular atrophy and interstitial
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Fig. 1. Schematic representation of factors
influencing kidney graft function and the
lesions observed in kidneys with chronic allo-
graft nephropathy, including transplant vascu-
lopathy (A), transplant glomerulopathy (B),
and tubular atrophy and interstitial fibrosis
(C). F344 to LEW renal transplantation at
days 30 to 60 (original magnification ×200).
fibrosis as background lesions observed in chronic allo-
graft nephropathy and aging kidneys.
CONCLUSION
The pathogenesis of chronic allograft nephropathy is
multifactorial and comprehends progression factors that
are alloantigen-independent and alloantigen-dependent
factors that are crucial for the development of chronic
allograft nephropathy. Figure 1 summarizes the most im-
portant factors involved in the development of chronic
allograft nephropathy, ultimately resulting in the lesions
described. Transplant vasculopathy is characterized by
intimal proliferation and can ultimately result in luminal
occlusion, antibodies reactive with endothelial cell anti-
gens and HLA antigens are thought to be involved. Trans-
plant glomerulopathy is characterized by duplications of
the glomerular basement membrane, and according to
our hypothesis antibodies reactive with GBM antigens
are involved in the development of these lesions. Both
glomerulopathy and vasculopathy are frequently found in
a background of interstitial fibrosis and tubular atrophy.
These background lesions are less well understood. Most
of the progression factors, including donor age, seem re-
sponsible for the development of these lesions. Replica-
tive senescence might be a mechanism by which tubular
atrophy develops. Risk factor analysis for chronic allo-
graft nephropathy in the absence of glomerular or vascu-
lar lesion revealed young recipient age, sensitization, and
late acute rejection episodes, suggesting the alloantigen-
dependent responses also play a role in this entity.
Although many factors have been associated with
chronic allograft nephropathy/chronic rejection, their rel-
ative contribution remains to be elucidated. Future re-
search on the role of humoral responses might open new
possibilities for treatment or prevention of chronic trans-
plant failure. In addition, more insights into accelerated
ageing of renal allografts might result in novel strategies
to prevent the background lesions.
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